Multicenter and prospective study to determine the satisfaction with actonel (risedronate sodium) [risedronic acid] 35mg once a week using biochemical markers of bone as a control, in postmenopausal women with osteoporosis

Trial Profile

Multicenter and prospective study to determine the satisfaction with actonel (risedronate sodium) [risedronic acid] 35mg once a week using biochemical markers of bone as a control, in postmenopausal women with osteoporosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2008

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms ROSPA-CTx
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top